Postnatal dexamethasone, respiratory and neurodevelopmental outcomes at two years in babies born extremely preterm
Open Access
- 19 July 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0181176
Abstract
Postnatal dexamethasone is associated with reduction in bronchopulmonary dysplasia. There remains, however, concern that its short-term benefits are accompanied by long-term adverse effects e.g. poorer neurodevelopmental outcomes. Our aim was to determine the effects of administration of postnatal dexamethasone on respiratory and neurodevelopmental outcome at two years of age after adjusting for neonatal and infant risk factors. The study included 412 infants born at 23–28 weeks of gestation, 29% had received postnatal dexamethasone. Two outcomes were examined, respiratory hospital admissions in the past 12 months and neurodevelopmental impairment. Logistic regression, adjusted for sex, birthweight z-score, gestation, maternal smoking, oxygen dependency at 36 weeks, airleak, patent ductus arteriosus, pulmonary haemorrhage, major ultrasound abnormality, mode of ventilation and age at assessment, was undertaken. After adjustment, postnatal dexamethasone was associated with significantly increased proportions of both respiratory hospital readmission: (0.35 vs 0.15, difference = 0.20; 95% CI: 0.08, 0.31) and neurodevelopmental impairment (0.59 vs 0.45, difference = 0.14; 95% CI: 0.02, 0.26). Postnatal dexamethasone use in extremely preterm infants is associated with increased risks of respiratory hospital admissions and neurodevelopmental impairment. These associations were not explained by excess neonatal morbidities.Keywords
Funding Information
- National Institute for Health Research
This publication has 19 references indexed in Scilit:
- Prenatal Glucocorticoid Treatment and Later Mental Health in Children and AdolescentsPLOS ONE, 2013
- Post-natal corticosteroids are associated with reduced expiratory flows in children born very pretermJournal of Paediatrics and Child Health, 2011
- Impact of Postnatal Corticosteroid Use on Neurodevelopment at 18 to 22 Months' Adjusted Age: Effects of Dose, Timing, and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight InfantsPediatrics, 2009
- Follow-up Study of a Randomized Controlled Trial of Postnatal Dexamethasone Therapy in Very Low Birth Weight Infants: Effects on Pulmonary Outcomes at Age 8 to 11 YearsThe Journal of Pediatrics, 2007
- Randomised trial of high frequency oscillatory ventilation or conventional ventilation in babies of gestational age 28 weeks or less: respiratory and neurological outcomes at 2 yearsArchives of Disease in Childhood - Fetal and Neonatal Edition, 2006
- Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-up Study: II. Respiratory Status, Growth, and Blood PressurePediatrics, 2005
- Follow-up at 15 Years of Preterm Infants From a Controlled Trial of Moderately Early Dexamethasone for the Prevention of Chronic Lung DiseasePediatrics, 2005
- Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of PrematurityNew England Journal of Medicine, 2004
- Postnatal steroid treatment and brain developmentArchives of Disease in Childhood - Fetal and Neonatal Edition, 2004
- High-Frequency Oscillatory Ventilation for the Prevention of Chronic Lung Disease of PrematurityNew England Journal of Medicine, 2002